Cellular immunity elicited by the BioNTech/Pfizer and Johnson & Johnson Covid-19 vaccines is effective against the Omicron coronavirus variant, according to a study, suggesting vaccines will protect against severe disease even if the antibody responses against the strain are not as strong or durable.
一项研究表明，由BioNTech/辉瑞(Pfizer)和强生(Johnson & Johnson)新冠疫苗引发的细胞免疫对Omicron变种有效，这似乎表明现有疫苗能够预防重症——即便针对该病毒株的抗体反应不那么强烈或持久。
您已阅读10%（413字），剩余90%（3870字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。